Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 0.00% is 100% below its 5-year average of 0.60%, near the low end of its 5-year range (0.00%–2.93%).
As of the fiscal period ended Tuesday, June 30, 2026. 100.00% below its 12-month average of 1.43%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
DEBT TO ASSETS RATIO
0.00%
DEBT TO ASSETS RATIO AVG TTM
1.43%
DEBT TO ASSETS RATIO AVG 3Y
1.02%
DEBT TO ASSETS RATIO AVG 5Y
0.60%
DEBT TO ASSETS RATIO AVG 10Y
1.29%
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-100.00%
CURRENT VS 3Y AVG
-100.00%
CURRENT VS 5Y AVG
-100.00%
CURRENT VS 10Y AVG
-100.00%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.09%
median of 874 covered companies
CURRENT VS SECTOR MEDIAN
-100.00%
vs the sector median at left
XORTX Therapeutics Inc.
Market Cap
$484571.00
Debt to Assets Ratio
0.00%
TTM Avg
1.43%
3Y Avg
1.02%
5Y Avg
0.60%
Market Cap
$521431.00
Debt to Assets Ratio
0.08%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$552749.00
Debt to Assets Ratio
0.25%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$389269.00
Debt to Assets Ratio
0.18%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$371384.00
Debt to Assets Ratio
0.05%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$819652.00
Debt to Assets Ratio
0.03%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| XORTX Therapeutics Inc. (XRTX) | $484571.00 | 0.00% | 1.43% | 1.02% | 0.60% |
| VivoSim Labs, Inc. (VIVS)vs › | $521431.00 | 0.08% | N/A | N/A | N/A |
| HCW Biologics Inc. (HCWB)vs › | $552749.00 | 0.25% | N/A | N/A | N/A |
| Niki BioSolutions, Inc. (NIKI)vs › | $389269.00 | 0.18% | N/A | N/A | N/A |
| Virax Biolabs Group Limited (VRAX)vs › | $371384.00 | 0.05% | N/A | N/A | N/A |
| CDT Equity Inc. (CDT)vs › | $661901.00 | 0.38% | N/A | N/A | N/A |
| SciSparc Ltd. (SPRC)vs › | $242924.00 | 0.05% | N/A | N/A | N/A |
| Ridgetech, Inc. (RDGT)vs › | $812262.00 | 0.00% | N/A | N/A | N/A |
| China SXT Pharmaceuticals, Inc. (SXTC)vs › | $819652.00 | 0.03% | N/A | N/A | N/A |
| Decoy Therapeutics Inc. (DCOY)vs › | $840509.00 | 0.00% | N/A | N/A | N/A |
Debt/Assets
0.0%
Debt/Equity
0.00
Current Ratio
3.59
Interest Coverage
N/A
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.70% |
| 2025-12-31 | 1.39% |
| 2025-09-30 | 2.10% |
| 2025-06-30 | 2.93% |
| 2025-03-31 | 0.45% |
| 2024-12-31 | 0.95% |
| 2024-09-30 | 1.60% |
| 2024-06-30 | 1.74% |
| 2024-03-31 | 0.23% |
| 2023-12-31 | 0.21% |
| 2023-09-30 | 0.43% |
| 2023-06-30 | 0.58% |
| 2023-03-31 | 0.64% |
| 2022-12-31 | 0.63% |
| 2022-09-30 | 0.85% |
| 2022-06-30 | 0.92% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 1.57% |
| 2019-12-31 | 4.67% |
| 2019-09-30 | 4.54% |
| 2019-06-30 | 4.32% |
| 2019-03-31 | 4.00% |
| 2018-12-31 | 3.42% |
| 2018-09-30 | 3.04% |
| 2018-06-30 | 2.53% |
| 2018-03-31 | 2.09% |
| 2017-12-31 | 44.16% |
| 2017-09-30 | 53.99% |
| 2017-05-31 | 47.78% |
| 2017-02-28 | 0.00% |
| 2016-11-30 | 36.51% |
| 2016-08-31 | 0.00% |
| 2016-05-31 | 0.00% |
| 2016-02-29 | 0.00% |
| 2015-11-30 | 0.00% |
| 2015-08-31 | 0.00% |
| 2015-05-31 | 0.00% |
| 2015-02-28 | 0.00% |
